Tofa 5 mg BID successful in treating refractory uveitis in reducing inflammation and reducing steroid dosage. Abs 1041 #ACR22 @RheumNow https://t.co/dtAEhW7dEG https://t.co/Xbw2iEsYHh

• Tofacitinib in Refractory Uveitis – an Observational Study - ACR Meeting Abstra…

Kahlenberg @Kahlenberglab et al. TYK2i deucravacitinib in SLE. Clinical efficacy (figure). Deucravacitinib suppressed IFN production, IFN-responsive gene expression, IFN-inducible proteins, B cell markers,serological biomarkers. @RheumNow #ACR22 Abstr#1000 https://t.co/zzkoPLOlSR https://t.co/znyG8N5pJ2

• Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarker…

Johnson et al TYK2i deucravacitinib does not inhibit haematologic pathways, Treg function, or IL-15 dependent NK cell function, that JAKi do. @rheumnow #ACR22 Abstr#0584 https://t.co/UTHzUjGmJN https://t.co/NUKKAv3tAr

• Non-Clinical Evaluations of Deucravacitinib and Janus Kinase Inhibitor Specific…

Trend of reduced opioid use when initiating biologics and JAKi in RA though effect size small and very high baseline use (>50%) in this insurance claims database. Residual pain and harm minimisation still areas of need. @RheumNow #ACR22 ABST0925 https://t.co/XGHu0fIMF0 https://t.co/PutNNQiKnY

• Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheu…

JAK and TYK-2 inhibitors and indications in SpA: ● Tofacitinib ➣ Pan JAKi (AS, PsA) ● Baricitinib ➣ JAK1,2 ● Upadacitinib ➣ JAK1 (AxSpA, PsA) ● Deucravacitinib ➣ TYK2 (PsA) Carol Langford, Year in Review #ACR22 @RheumNow https://t.co/EMLEvptySS

Across 9 trials of Upadacitinib in RA, PsA and AS, 40%–50% of patients had ≥ 2 CV risk factors, ≥ 65 years 6%–23%. Rates of adjudicated MACE and VTE with UPA were infrequent, consistent with background rates in RA, PsA, and AS Abst 0510 https://t.co/HDkQ6ELnAy #ACR22 @RheumNow https://t.co/SRJYdFFNIQ

• MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthriti…

Post hoc analysis from the SELECT-PsA 1 trial by Dr. @DrLauraCoates and team: 💊Pts on UPA showed greater improvement from BL in RAPID3 vs. ADA in all visits 💊Pts on UPA had better responses in all assessments vs. PBO Reassuring data. #ACR22 @RheumNow ABST0192 https://t.co/NgeUU5bPPf